SARS-CoV-2 Impact on Red Blood Cell Morphology

SARS-CoV-2 Impact on Red Blood Cell Morphology

Severe COVID-19 alters the biochemical and morphological characteristics of blood cells in a wide variety of ways. To date, however, the vast majority of research has been devoted to the study of leukocytes, while erythrocyte morphological changes have received significantly less attention. The aim...

Full description

Bibliographic Details
Main Authors:	Kirill A. Kondratov, Alexander A. Artamonov, Vladimir Yu. Mikhailovskii, Anastasiya A. Velmiskina, Sergey V. Mosenko, Evgeniy A. Grigoryev, Anna Yu. Anisenkova, Yuri V. Nikitin, Svetlana V. Apalko, Natalya N. Sushentseva, Andrey M. Ivanov, Sergey G. Scherbak
Format:	Article
Language:	English
Published:	MDPI AG 2023-10-01
Series:	Biomedicines
Subjects:	COVID-19 erythrocyte red blood cells cytokine storm severe COVID-19 low-voltage scanning electron microscopy
Online Access:	https://www.mdpi.com/2227-9059/11/11/2902

Similar Items

Major predictive risk factors for а cytokine storm in COVID-19 patients (a retrospective clinical trials)
by: Anna Yu. Anisenkova, et al.
Published: (2021-03-01)

Basic Predictive Risk Factors for Cytokine Storms in COVID-19 Patients
by: Sergey G. Shcherbak, et al.
Published: (2021-11-01)

Predictive role of erythrocytes in assessment of COVID-19 outcomes
by: Yuri N. Smolyakov, et al.
Published: (2023-07-01)

COVID-19 biobank: features of the cytokine profile
by: N. N. Sushentseva, et al.
Published: (2020-12-01)

Parameters and Morphological Changes of Erythrocytes and Platelets of COVID-19 Subjects: A Longitudinal Cohort Study
by: Shen L, et al.
Published: (2023-03-01)

Changes in the electrical and viscoelastic parameters of erythrocytes in patients with manifestations of metabolic syndrome, COVID-19 convalescents, when exposed to citicoline in an in vitro experiment
by: Margarita V. Kruchinina, et al.
Published: (2023-11-01)

Impact of the seventh day nucleated red blood cell count on mortality in COVID-19 intensive care unit patients: A retrospective case-control study
by: Düz Muhammed Emin, et al.
Published: (2023-01-01)

Tocilizumab therapy for COVID-19: A comparison of subcutaneous and intravenous therapies
by: Monica A. Kaminski, et al.
Published: (2020-12-01)

Clinical Consequences for Individuals Treated with Tocilizumab for Serious COVID-19 Infection
by: Al Shaimaa Ibrahim Rabie, et al.
Published: (2023-02-01)

Emerging complications of COVID-19 in a subset of Indian population: a pathological review with clinico-radiological case scenarios
by: Aniket Agarwal, et al.
Published: (2022-02-01)

Mixed storm in SARS‐CoV‐2 infection: A narrative review and new term in the Covid‐19 era
by: Basil Mohammed Alomair, et al.
Published: (2023-04-01)

Research into Morphofunctional Characteristics of Erythrocytes in COVID-19 Patients
by: Victor Revin, et al.
Published: (2022-02-01)

A reduced fixed dose of Tocilizumab 200 mg compared to 400 mg in patients with severe COVID-19 disease
by: Stela COJOCARU, et al.
Published: (2024-10-01)

When Does the Cytokine Storm Begin in COVID-19 Patients? A Quick Score to Recognize It
by: Stefano Cappanera, et al.
Published: (2021-01-01)

The Management of Cytokine Storm in COVID-19
by: Cleopas Martin Rumende, et al.
Published: (2020-10-01)

Evaluation of the economic effect of biological therapy in patients with severe COVID-19 and cytokine storm
by: M. Yu. Frolov, et al.
Published: (2021-02-01)

Therapeutic Plasma Exchanges in Combination with High-Dose Steroid-Induced Immunosuppression as an Ultima Ratio Therapy in Severe Coronavirus Disease 2019 (COVID-19): A Case-Series Report
by: Janikowska A, et al.
Published: (2022-02-01)

Immune and Metabolic Response to Covid-19 Infection: Review for Molecular Pathways
by: Andrew K. Martusevich, et al.
Published: (2020-09-01)

Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients’ treatment
by: Alexey I. Khripun, et al.
Published: (2022-06-01)

Role of mast cells in the pathogenesis of severe lung damage in COVID-19 patients
by: Andrey V. Budnevsky, et al.
Published: (2022-12-01)

Development of an In Vitro Model of SARS-CoV-Induced Acute Lung Injury for Studying New Therapeutic Approaches
by: Yulia A. Shevtsova, et al.
Published: (2022-09-01)

Pre-existing asthma as a comorbidity does not modify cytokine responses and severity of COVID-19
by: Jian Luo, et al.
Published: (2021-07-01)

Interstitial inflammation and pulmonary fibrosis in COVID-19: The potential role of cytostatic therapy for severe lung injury
by: Elena V. Filimonova, et al.
Published: (2022-01-01)

Secretory Phospholipase A2 and Interleukin-6 Levels as Predictive Markers of the Severity and Outcome of Patients with COVID-19 Infections
by: Stanislav Urazov, et al.
Published: (2023-03-01)

The role of systemic immune activation in the development of thyroid dysfunction in COVID-19
by: Evgenia A. Kolpakova, et al.
Published: (2022-11-01)

Immune and ionic mechanisms mediating the effect of dexamethasone in severe COVID-19
by: Ameet A. Chimote, et al.
Published: (2023-03-01)

Pathophysiological Changes in Erythrocytes Contributing to Complications of Inflammation and Coagulation in COVID-19
by: Prashilla Soma, et al.
Published: (2022-06-01)

Editorial: Pathological Changes in Erythrocytes During Inflammation and Infection
by: Janette Bester, et al.
Published: (2022-06-01)

Clinical observation of the course of COVID-19 in patients with multiple sclerosis during ocrelizumab therapy: two clinical cases
by: E. V. Popova, et al.
Published: (2021-08-01)

Intensive Care Patients from the First COVID-19 Wave: One-Year Survival after Tocilizumab Treatment
by: Gabriele Melegari, et al.
Published: (2021-11-01)

Thrombotic storm, hemostasis disorders and thromboinflammation in COVID-19
by: A. D. Makatsariya, et al.
Published: (2021-11-01)

Diabetes Mellitus—A Risk Factor for Unfavourable Outcome in COVID-19 Patients—The Experience of an Infectious Diseases Regional Hospital
by: Egidia Miftode, et al.
Published: (2021-06-01)

The analysis of Fe-dependent serum enzymes in severe COVID-19 with a pulmonary thrombotic event
by: Jarosław Bakiera, et al.
Published: (2023-01-01)

Interleukin 6 Levels and their Correlation with Various Hematological and Biochemical Parameters in Covid-19 Patients
by: Ruaa Salim Rasheed, et al.
Published: (2023-04-01)

Effectiveness of Tocilizumab in reducing inflammatory response associated with COVID-19 pneumonia at Islamabad Medical Complex, Islamabad
by: Abdul Naeem, et al.
Published: (2023-04-01)

Patients with hemodialysis-induced hypoxemia had a poor prognosis of COVID-19
by: Masataro Toda, et al.
Published: (2022-05-01)

The Reasons for Higher Mortality Rate in Opium Addicted Patients with COVID-19: A Narrative Review
by: Amirhossein DOLATI-SOMARIN, et al.
Published: (2021-02-01)

Clinical case of COVID-19 in a patient treated with alemtuzumab
by: E. V. Popova
Published: (2021-12-01)

Longitudinal multi-omics transition associated with fatality in critically ill COVID-19 patients
by: Chaoyang Sun, et al.
Published: (2021-03-01)

Clinical and prognostic value of parameters of cytokine regulation in oxygen-dependent patients with the coronavirus disease COVID-19
by: O. V. Riabokon, et al.
Published: (2023-08-01)